Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:08:51.972Z.
Calculation as of: 2026-10-06T16:08:51.972Z.
Quote observation: 2026-10-06T16:05:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5b41231b7583dd96ab78187317b9f32b3728f458d8f95d0d00832bd8f136f307
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Neumora Therapeutics, Inc. Common Stock
Market Cap
$91.83M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$93.80M
EV/FCF Ratio
N/A
TTM Avg
5.07x
3Y Avg
5.07x
5Y Avg
5.07x
Market Cap
$89.34M
EV/FCF Ratio
22.05x
TTM Avg
56.27x
3Y Avg
59.65x
5Y Avg
59.65x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neumora Therapeutics, Inc. Common Stock (NMRA) | $91.83M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $91.33M | N/A | N/A | N/A | N/A |
| Rallybio Corporation (RLYB)vs › | $90.85M | N/A | 0.18x | 0.18x | 0.18x |
| Equillium, Inc. (EQ)vs › | $90.73M | N/A | 5.17x | 5.17x | 5.17x |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $90.13M | N/A | N/A | N/A | N/A |
| Biomea Fusion, Inc. (BMEA)vs › | $93.01M | N/A | N/A | N/A | N/A |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $93.80M | N/A | 5.07x | 5.07x | 5.07x |
| ImmuCell Corporation (ICCC)vs › | $89.34M | 22.05x | 56.27x | 59.65x | 59.65x |
| Conexeu Sciences Inc. (CNXU)vs › | $96.60M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.90M | 5.88x | 5.69x | 5.19x | 9.05x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
